A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

J Neurooncol. 2017 Jun;133(2):443-445. doi: 10.1007/s11060-017-2447-3. Epub 2017 Apr 22.

Authors

Stéphane Goutagny¹, Marco Giovannini², Michel Kalamarides³

Affiliations

¹ Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, 100 boulevard du General Leclerc, 92100, Clichy, France.
² University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095-1624, USA.
³ Neurochirurgie, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75013, Paris, France. michel.kalamarides@aphp.fr.

PMID: 28434114
DOI: 10.1007/s11060-017-2447-3

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Disease Progression
Everolimus / adverse effects
Everolimus / therapeutic use*
Humans
Neurofibromatosis 2 / drug therapy*
Neuroma, Acoustic / drug therapy*
Treatment Outcome
Tumor Burden

Substances

Antineoplastic Agents
Everolimus